Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Maoping Cai; Xian-Lu Song; Xin-An Li; Mingkun Chen; Jiading Guo; Dong-Hua Yang; Zhanghui Chen; Shan-Chao Zhao

doi:10.1016/j.drup.2023.100962

Current therapy and drug resistance in metastatic castration-resistant prostate cancer

Drug Resist Updat. 2023 May:68:100962. doi: 10.1016/j.drup.2023.100962. Epub 2023 Apr 14.

Authors

Maoping Cai¹, Xian-Lu Song², Xin-An Li³, Mingkun Chen⁴, Jiading Guo⁵, Dong-Hua Yang⁶, Zhanghui Chen⁷, Shan-Chao Zhao⁸

Affiliations

¹ Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China; The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China; Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang 524045, Guangdong, PR China.
² Department of Radiotherapy, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, PR China.
³ School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, Guangdong, PR China.
⁴ Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China; The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, PR China.
⁵ Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China; The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China.
⁶ New York College of Traditional Chinese Medicine, Mineola 11501, NY, USA. Electronic address: Dong-hua.yang@nyctcm.edu.
⁷ Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang 524045, Guangdong, PR China. Electronic address: zjcell@126.com.
⁸ Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China; The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, PR China. Electronic address: lulululu@smu.edu.cn.

PMID: 37068396
DOI: 10.1016/j.drup.2023.100962

Abstract

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.

Keywords: Androgen receptor signaling inhibitors (ARSIs); Chemotherapy; Drug resistance; Metastatic castration-resistance prostate cancer (mCRPC); Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi).

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Drug Resistance, Neoplasm
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Prostatic Neoplasms, Castration-Resistant* / pathology
Signal Transduction
Taxoids

Substances

Taxoids